Why Nvidia Shares Are Falling

NVIDIA Corporation (NASDAQ: NVDA) shares are trading lower by 3.27% to $116.81 Monday morning. NVIDIA shares are trading lower on continued downward momentum in sympathy with Advanced Micro Devices, Inc. (NASDAQ: AMD) after the co

NVIDIA Corporation (NASDAQ:NVDA) shares are trading lower by 3.27% to $116.81 Monday morning. NVIDIA shares are trading lower on continued downward momentum in sympathy with Advanced Micro Devices, Inc. (NASDAQ:AMD) after the company last week lowered its third-quarter sales guidance below analyst estimates.

What Happened?

AMD sees preliminary third quarter revenue of approximately $5.6 billion, lower than prior outlook of $6.7 billion plus or minus $200 million, primarily due to weaker Client segment revenue.

“The PC market weakened significantly in the quarter,” said AMD Chair and CEO Dr. Lisa Su. “While our product portfolio remains very strong, macroeconomic conditions drove lower than expected PC demand and a significant inventory correction across the PC supply chain.”

“As we navigate the current market conditions, we are pleased with the performance of our Data Center, Embedded, and Gaming segments and the strength of our diversified business model and balance sheet. We remain focused on delivering our leadership product roadmap and look forward to launching our next-generation 5nm data center and graphics products later this quarter,” Su Stated.

See Also: US Adds 263,000 Jobs In September As Labor Market Tightens: How Will The Fed Respond?

According to data from Benzinga Pro, Nvidia has a 52-week high of $346.47 and a 52-week low of $116.70.

Total
0
Shares
Related Posts
Read More

Star Equity Holdings And 2 Other Stocks Under $2 Insiders Are Aggressively Buying

US crude oil futures traded sharply higher this morning on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

AWRE

Read More

The Week Ahead In Biotech: Earnings Kickstart With J&J And Biogen, Albireo Awaits FDA Decisions, More IPOs

Biotech stocks were down for a second week in a row, as they retreated along with the broader market amid macro concerns. Consumer price inflation data released during the week stoked rate hike fears, and exerted negative pressure on stocks. There were very few stock-specific catalysts, barring a few preannouncements, stock offerings, and a slew of initial public offerings.

ABT